M S Agarwal1, K E Hitchcock1, C G Morris1, T J George2, W M Mendenhall1, R A Zlotecki1. 1. Department of Radiat ion Oncology, University of Florida College of Medicine, Gainesville, FL, U.S.A. 2. Department of Medicine, University of Florida College of Medicine, Gainesville, FL, U.S.A.
Abstract
Purpose: We report our institution's treatment techniques, disease outcomes, and complication rates after radiotherapy for the management of anal canal carcinoma with intensity-modulated radiotherapy (imrt) and concurrent chemotherapy relative to prior cases managed with 3-dimensional conformal radiotherapy (3D-crt). Methods: In a retrospective review of the medical records of 21 patients diagnosed with biopsy-proven stage i (23%), stage ii (27%), or stage iii (50%) squamous-cell carcinoma of the anal canal treated with curative chemotherapy and imrt between July 2009 and December 2014, patient outcomes were determined. Results for patients treated with 3D-crt by the same group were previously reported. The median initial radiation dose to the pelvic and inguinal nodes at risk was 45 Gy (range: 36-50.4 Gy), and the median total dose, including local anal canal primary tumour boost, was 59.4 Gy (range: 41.4-61.2 Gy). Patients received those doses over a median of 32 fractions (range: 23-34 fractions). Chemotherapy consisted of 2 cycles of concurrent fluorouracil-cisplatin (45%) or fluorouracil-mitomycin C (55%). Results: Median follow-up was 3.1 years (range: 0.38-6.4 years). The mean includes a patient who died of septic shock at 38 days. The 3-year rates of overall survival, metastasis-free survival, locoregional control, and colostomy-free survival were 95%, 100%, 100%, and 100% respectively. No patients underwent abdominoperitoneal resection after chemoradiotherapy or required diverting colostomy during or after treatment. Those outcomes compare favourably with the previously published series that used 3D-crt with or without brachytherapy in treating anal canal cancers. Of the 21 patients in the present series, 10 (48%) experienced acute grade 3, 4, or 5 toxicities related to treatment. Conclusions: The recommended use of imrt with concurrent chemotherapy as an improvement over 3D-crt for management of anal canal carcinoma achieves a high probability of local control and colostomy-free survival without excessive risk for acute or late treatment-related toxicities.
Purpose: We report our institution's treatment techniques, disease outcomes, and complication rates after radiotherapy for the management of anal canal carcinoma with intensity-modulated radiotherapy (imrt) and concurrent chemotherapy relative to prior cases managed with 3-dimensional conformal radiotherapy (3D-crt). Methods: In a retrospective review of the medical records of 21 patients diagnosed with biopsy-proven stage i (23%), stage ii (27%), or stage iii (50%) squamous-cell carcinoma of the anal canal treated with curative chemotherapy and imrt between July 2009 and December 2014, patient outcomes were determined. Results for patients treated with 3D-crt by the same group were previously reported. The median initial radiation dose to the pelvic and inguinal nodes at risk was 45 Gy (range: 36-50.4 Gy), and the median total dose, including local anal canal primary tumour boost, was 59.4 Gy (range: 41.4-61.2 Gy). Patients received those doses over a median of 32 fractions (range: 23-34 fractions). Chemotherapy consisted of 2 cycles of concurrent fluorouracil-cisplatin (45%) or fluorouracil-mitomycin C (55%). Results: Median follow-up was 3.1 years (range: 0.38-6.4 years). The mean includes a patient who died of septic shock at 38 days. The 3-year rates of overall survival, metastasis-free survival, locoregional control, and colostomy-free survival were 95%, 100%, 100%, and 100% respectively. No patients underwent abdominoperitoneal resection after chemoradiotherapy or required diverting colostomy during or after treatment. Those outcomes compare favourably with the previously published series that used 3D-crt with or without brachytherapy in treating anal canal cancers. Of the 21 patients in the present series, 10 (48%) experienced acute grade 3, 4, or 5 toxicities related to treatment. Conclusions: The recommended use of imrt with concurrent chemotherapy as an improvement over 3D-crt for management of anal canal carcinoma achieves a high probability of local control and colostomy-free survival without excessive risk for acute or late treatment-related toxicities.
Authors: Lisa A Kachnic; Henry K Tsai; John J Coen; Lawrence S Blaszkowsky; Kevan Hartshorn; Eunice L Kwak; John D Willins; David P Ryan; Theodore S Hong Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-20 Impact factor: 7.038
Authors: Michael T Milano; Ashesh B Jani; Karl J Farrey; Carla Rash; Ruth Heimann; Steven J Chmura Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Joseph C Hodges; Prajnan Das; Cathy Eng; Andrew G Reish; A Sam Beddar; Marc E Delclos; Sunil Krishnan; Christopher H Crane Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-21 Impact factor: 7.038
Authors: Anna N Rabbani; Robert A Zlotecki; Jessica Kirwan; Thomas J George; Christopher G Morris; W Robert Rout; William M Mendenhall Journal: Am J Clin Oncol Date: 2010-02 Impact factor: 2.339
Authors: Joseph K Salama; Loren K Mell; David A Schomas; Robert C Miller; Kiran Devisetty; Ashesh B Jani; Arno J Mundt; John C Roeske; Stanley L Liauw; Steven J Chmura Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: Robert J Myerson; Michael C Garofalo; Issam El Naqa; Ross A Abrams; Aditya Apte; Walter R Bosch; Prajnan Das; Leonard L Gunderson; Theodore S Hong; J J John Kim; Christopher G Willett; Lisa A Kachnic Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-29 Impact factor: 7.038
Authors: Melissa P Mitchell; Mirna Abboud; Cathy Eng; A Sam Beddar; Sunil Krishnan; Marc E Delclos; Christopher H Crane; Prajnan Das Journal: Am J Clin Oncol Date: 2014-10 Impact factor: 2.339